Literature DB >> 9214422

Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography.

A U Wells1, D M Hansell, M B Rubens, A D King, D Cramer, C M Black, R M du Bois.   

Abstract

OBJECTIVE: Thin-section computed tomography (CT) provides a sensitive and reproducible method of quantifying the morphologic extent of disease in the clinical management of fibrosing alveolitis associated with systemic sclerosis (FASSc). The aim of this study was to determine which indices of lung function best reflect the extent of disease on CT in FASSc, and to determine the independent influences of smoking history, extent of fibrosing alveolitis, demographic features, and concurrent treatment upon functional impairment in FASSc.
METHODS: Sixty-four patients with FASSc were studied using CT and static and exercise lung function testing. Statistical relationships were determined by multiple regression analyses.
RESULTS: Five patients with overt pulmonary hypertension were characterized by severe impairment in 3 indices of lung function: diffusing capacity for carbon monoxide (DLCO), DLCO adjusted for alveolar volume (KCO), and arterial partial pressure of oxygen. On multiple regression analysis, the major determinant of functional impairment was the extent of fibrosing alveolitis on CT. A history of smoking was independently associated with preservation of total lung capacity and depression of KCO, but did not otherwise influence functional-morphologic correlations. The percent predicted DLCO correlated better with extent of disease on CT (r = -0.70) than did oxygen desaturation on exercise (r = 0.55), the physiologic component of the clinical-radiographic-physiologic score (CRP index) (r = 0.52), or other indices of lung function. Lung volume measures correlated poorly with disease extent on CT.
CONCLUSION: The percent predicted DLCO best reflects the extent of fibrosing alveolitis in FASSc, and therefore should be measured in routine evaluations. Exercise testing may also have a useful role in staging the severity of pulmonary fibrosis, but the CRP index offers no additional advantage over the DLCO and exercise testing.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9214422     DOI: 10.1002/1529-0131(199707)40:7<1229::AID-ART6>3.0.CO;2-W

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  24 in total

1.  Radiographic (ILO) readings predict arterial oxygen desaturation during exercise in subjects with asbestosis.

Authors:  Y C G Lee; B Singh; S C Pang; N H de Klerk; D R Hillman; A W Musk
Journal:  Occup Environ Med       Date:  2003-03       Impact factor: 4.402

Review 2.  Evidence-based management of rapidly progressing systemic sclerosis.

Authors:  Dinesh Khanna; Christopher P Denton
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-06       Impact factor: 4.098

3.  T-889C IL-1alpha promoter polymorphism influences the response to oral cyclophosphamide in scleroderma patients with alveolitis.

Authors:  Lorenzo Beretta; Francesca Cappiello; Morena Barili; Francesca Bertolotti; Raffaella Scorza
Journal:  Clin Rheumatol       Date:  2006-04-25       Impact factor: 2.980

Review 4.  Interstitial lung disease in systemic sclerosis.

Authors:  O Kaloudi; I Miniati; S Alari; M Matucci-Cerinic
Journal:  Intern Emerg Med       Date:  2007-12-17       Impact factor: 3.397

5.  Fast 1.5 T chest MRI for the assessment of interstitial lung disease extent secondary to systemic sclerosis.

Authors:  Iago Pinal-Fernandez; Victor Pineda-Sanchez; Esther Pallisa-Nuñez; Carmen Pilar Simeon-Aznar; Albert Selva-O'Callaghan; Vicente Fonollosa-Pla; Miquel Vilardell-Tarres
Journal:  Clin Rheumatol       Date:  2016-04-23       Impact factor: 2.980

Review 6.  Interstitial lung disease in systemic sclerosis: current and future treatment.

Authors:  Roberto Giacomelli; Vasiliki Liakouli; Onorina Berardicurti; Piero Ruscitti; Paola Di Benedetto; Francesco Carubbi; Giuliana Guggino; Salvatore Di Bartolomeo; Francesco Ciccia; Giovanni Triolo; Paola Cipriani
Journal:  Rheumatol Int       Date:  2017-01-06       Impact factor: 2.631

Review 7.  Pulmonary function testing in idiopathic interstitial pneumonias.

Authors:  Fernando J Martinez; Kevin Flaherty
Journal:  Proc Am Thorac Soc       Date:  2006-06

Review 8.  The promising role of lung ultrasound in systemic sclerosis.

Authors:  A Delle Sedie; L Carli; E Cioffi; S Bombardieri; L Riente
Journal:  Clin Rheumatol       Date:  2012-07-29       Impact factor: 2.980

9.  Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis.

Authors:  Sabrina Hoa; Sasha Bernatsky; Russell J Steele; Murray Baron; Marie Hudson
Journal:  Rheumatology (Oxford)       Date:  2020-05-01       Impact factor: 7.580

Review 10.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.